ARS Pharmaceuticals Gears Up For Q1 Print; Here Are The Recent Forecast Changes From Wall Street's Most Accurate Analysts

Benzinga Earnings

05/15

ARS Pharmaceuticals, Inc. (NASDAQ:SPRY) will release earnings for its first quarter before the opening bell on Friday, May 15.

Analysts expect the San Diego, California-based company to report quarterly loss of 54 cents per share, versus a loss of 35 cents per share in the year-ago period. The consensus estimate for ARS Pharmaceuticals' quarterly revenue is $22.12 million (it reported $7.97 million last year), according to Benzinga Pro.

On May 13, ARS Pharmaceuticals named Donn Casale as president.

Shares of ARS Pharmaceuticals fell 0.9% to close at $7.94 on Thursday.

Benzinga readers can access the latest analyst ratings on the Analyst Stock Ratings page. Readers can sort by stock ticker, company name, analyst firm, rating change or other variables.

Let's have a look at how Benzinga's most-accurate analysts have rated the company in the recent period.

Roth Capital analyst Jason Wittes initiated coverage on the stock with a Buy rating and a price target of $40 on Sept. 4, 2025. This analyst has an accuracy rate of 54%.
Scotiabank analyst Louise Chen initiated coverage on the stock with a Sector Outperform rating and a price target of $30 on March 7, 2025. This analyst has an accuracy rate of 60%.
Raymond James analyst Ryan Deschner maintained a Strong Buy rating and raised the price target from $26 to $28 on Jan. 14, 2025. This analyst has an accuracy rate of 80%.

Considering buying SPRY stock? Here’s what analysts think:

Photo via Shutterstock

免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。

热议股票

1
2
3
4
5
6
7
8
9
10

{"basename":"/hans","ssrTDKData":{"titleTemplate":"%s - 老虎证券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎证券,老虎证券开户,老虎券商,老虎证券官网,老虎证券app,tigertrade老虎证券,股票,炒股,新加坡股票交易平台,投资,投资理财","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.0a0bd8dc.png","ogUrl":"https://www.itiger.com/hans/news/2635709887"},"companyName":"老虎证券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2635709887\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2635709887?lang=zh_CN&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-05-15 14:08","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2635709887","market":"us","top_or_hot":-1,"title":"ARS Pharmaceuticals Gears Up For Q1 Print; Here Are The Recent Forecast Changes From Wall Street's Most Accurate Analysts","media":"Benzinga Earnings","content":"<html><body><p><strong>ARS Pharmaceuticals, Inc</strong>. (NASDAQ:SPRY) will release earnings for its first quarter before the opening bell on Friday, May 15.</p>\n<p>Analysts expect the San Diego, California-based company to report quarterly loss of 54 cents per share, versus a loss of 35 cents per share in the year-ago period. The consensus estimate for ARS Pharmaceuticals' quarterly revenue is $22.12 million (it reported $7.97 million last year), according to Benzinga Pro.</p>\n<p>On May 13, ARS Pharmaceuticals named Donn Casale as president.</p>\n<p>Shares of ARS Pharmaceuticals fell 0.9% to close at $7.94 on Thursday.</p>\n<p>Benzinga readers can access the latest analyst ratings on the Analyst Stock Ratings page. Readers can sort by stock ticker, company name, analyst firm, rating change or other variables.</p>\n<p>Let's have a look at how Benzinga's most-accurate analysts have rated the company in the recent period.</p>\n<ul>\n<li>Roth Capital analyst Jason Wittes initiated coverage on the stock with a Buy rating and a price target of $40 on Sept. 4, 2025. This analyst has an accuracy rate of 54%.</li>\n<li>Scotiabank analyst Louise Chen initiated coverage on the stock with a Sector Outperform rating and a price target of $30 on March 7, 2025. This analyst has an accuracy rate of 60%.</li>\n<li>Raymond James analyst Ryan Deschner maintained a Strong Buy rating and raised the price target from $26 to $28 on Jan. 14, 2025. This analyst has an accuracy rate of 80%.</li>\n</ul>\n<p>Considering buying SPRY stock? Here’s what analysts think: </p>\n<figure><img decoding=\"async\" height=\"479\" loading=\"lazy\" sizes=\"(max-width: 1024px) 100vw, 1024px\" src=\"https://editorial-assets.benzinga.com/wp-content/uploads/2026/05/15020654/image-398-1024x479.png\" srcset=\"https://editorial-assets.benzinga.com/wp-content/uploads/2026/05/15020654/image-398-1024x479.png 1024w,https://editorial-assets.benzinga.com/wp-content/uploads/2026/05/15020654/image-398-300x140.png 300w,https://editorial-assets.benzinga.com/wp-content/uploads/2026/05/15020654/image-398-768x359.png 768w,https://editorial-assets.benzinga.com/wp-content/uploads/2026/05/15020654/image-398.png 1252w\" width=\"1024\"/></figure>\n<p><em>Photo via Shutterstock</em></p></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>ARS Pharmaceuticals Gears Up For Q1 Print; Here Are The Recent Forecast Changes From Wall Street's Most Accurate Analysts</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nARS Pharmaceuticals Gears Up For Q1 Print; Here Are The Recent Forecast Changes From Wall Street's Most Accurate Analysts\n</h2>\n\n<h4 class=\"meta\">\n\n\n<div class=\"head\" \">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/d08bf7808052c0ca9deb4e944cae32aa);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Benzinga Earnings </p>\n<p class=\"h-time\">2026-05-15 14:08</p>\n</div>\n\n</div>\n\n\n</h4>\n\n</header>\n<article>\n<html><body><p><strong>ARS Pharmaceuticals, Inc</strong>. (NASDAQ:SPRY) will release earnings for its first quarter before the opening bell on Friday, May 15.</p>\n<p>Analysts expect the San Diego, California-based company to report quarterly loss of 54 cents per share, versus a loss of 35 cents per share in the year-ago period. The consensus estimate for ARS Pharmaceuticals' quarterly revenue is $22.12 million (it reported $7.97 million last year), according to Benzinga Pro.</p>\n<p>On May 13, ARS Pharmaceuticals named Donn Casale as president.</p>\n<p>Shares of ARS Pharmaceuticals fell 0.9% to close at $7.94 on Thursday.</p>\n<p>Benzinga readers can access the latest analyst ratings on the Analyst Stock Ratings page. Readers can sort by stock ticker, company name, analyst firm, rating change or other variables.</p>\n<p>Let's have a look at how Benzinga's most-accurate analysts have rated the company in the recent period.</p>\n<ul>\n<li>Roth Capital analyst Jason Wittes initiated coverage on the stock with a Buy rating and a price target of $40 on Sept. 4, 2025. This analyst has an accuracy rate of 54%.</li>\n<li>Scotiabank analyst Louise Chen initiated coverage on the stock with a Sector Outperform rating and a price target of $30 on March 7, 2025. This analyst has an accuracy rate of 60%.</li>\n<li>Raymond James analyst Ryan Deschner maintained a Strong Buy rating and raised the price target from $26 to $28 on Jan. 14, 2025. This analyst has an accuracy rate of 80%.</li>\n</ul>\n<p>Considering buying SPRY stock? Here’s what analysts think: </p>\n<figure><img decoding=\"async\" height=\"479\" loading=\"lazy\" sizes=\"(max-width: 1024px) 100vw, 1024px\" src=\"https://editorial-assets.benzinga.com/wp-content/uploads/2026/05/15020654/image-398-1024x479.png\" srcset=\"https://editorial-assets.benzinga.com/wp-content/uploads/2026/05/15020654/image-398-1024x479.png 1024w,https://editorial-assets.benzinga.com/wp-content/uploads/2026/05/15020654/image-398-300x140.png 300w,https://editorial-assets.benzinga.com/wp-content/uploads/2026/05/15020654/image-398-768x359.png 768w,https://editorial-assets.benzinga.com/wp-content/uploads/2026/05/15020654/image-398.png 1252w\" width=\"1024\"/></figure>\n<p><em>Photo via Shutterstock</em></p></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"SPRY","symbol_name":"ARS PHARMACEUTICALS INC","start_time":0,"source_url":"https://www.benzinga.com/analyst-stock-ratings/price-target/26/05/52588230/ars-pharmaceuticals-gears-up-for-q1-print-here-are-the-recent-forecast-changes-from-wall-streets-most-accurate-analysts","article_id":"2635709887","we_media_id":"1052270027","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2635709887","pubTimestamp":1778825313,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Benzinga Earnings","introduction":"Stock Market Quotes, Business News, Financial News, Trading Ideas, and Stock Research by Professionals","home_visible":0,"id":"1052270027","head_image":"https://static.tigerbbs.com/d08bf7808052c0ca9deb4e944cae32aa"},"summary":"ARS Pharmaceuticals, Inc. (NASDAQ: SPRY) to release first quarter earnings on May 15 before opening bell. Analysts expect a loss of 54 cents per share.","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"SPRY":"ARS PHARMACEUTICALS INC","BK4139":"生物科技"},"translate_title":"ARS Pharmaceuticals为第一季度印刷做好准备；以下是华尔街最准确的分析师最近的预测变化","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"SPRY":1},"content_text":"ARS Pharmaceuticals, Inc. (NASDAQ:SPRY) will release earnings for its first quarter before the opening bell on Friday, May 15.\nAnalysts expect the San Diego, California-based company to report quarterly loss of 54 cents per share, versus a loss of 35 cents per share in the year-ago period. The consensus estimate for ARS Pharmaceuticals' quarterly revenue is $22.12 million (it reported $7.97 million last year), according to Benzinga Pro.\nOn May 13, ARS Pharmaceuticals named Donn Casale as president.\nShares of ARS Pharmaceuticals fell 0.9% to close at $7.94 on Thursday.\nBenzinga readers can access the latest analyst ratings on the Analyst Stock Ratings page. Readers can sort by stock ticker, company name, analyst firm, rating change or other variables.\nLet's have a look at how Benzinga's most-accurate analysts have rated the company in the recent period.\n\nRoth Capital analyst Jason Wittes initiated coverage on the stock with a Buy rating and a price target of $40 on Sept. 4, 2025. This analyst has an accuracy rate of 54%.\nScotiabank analyst Louise Chen initiated coverage on the stock with a Sector Outperform rating and a price target of $30 on March 7, 2025. This analyst has an accuracy rate of 60%.\nRaymond James analyst Ryan Deschner maintained a Strong Buy rating and raised the price target from $26 to $28 on Jan. 14, 2025. This analyst has an accuracy rate of 80%.\n\nConsidering buying SPRY stock? Here’s what analysts think: \n\nPhoto via Shutterstock","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":true,"editions":null,"column":"","sentiment":"0","news_tag":"express","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"}}}